Mizagliflozin is an investigational first-in-class, oral, small molecule drug candidate that reduces postprandial glucose absorption, secretion of insulin, and secretion of gastric inhibitory peptide (GIP). The molecule is being developed by Vogenx for the treatment of PBH and gastroparesis, both debilitating diseases with high unmet medical need in underserved patient populations. Vogenx is also evaluating mizagliflozin as a treatment for an rare metabolic disease. Mizagliflozin has been administered to over 500 subjects in clinical studies and has shown to be safe and well-tolerated. 

VGX-2857 is an investigational drug candidate under evaluation for the treatment of obesity and weight maintenance.